Overview

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma

Status:
Recruiting

Trial end date:
2024-11-20

Target enrollment:

Participant gender:

Summary

Study CC-90010-GBM-002 is for newly diagnosed WHO Grade IV glioblastoma to determine the safety and tolerability and evaluate escalating doses of the investigational drug CC-90010 when combined with standard of care treatment temozolomide (TMZ) with or without radiotherapy (RT). The standard of care for ndGBM includes surgical resection to the extent that is safely feasible, followed by RT plus concomitant TMZ chemotherapy, and up to 6 months of adjuvant TMZ. The study also aims to determine whether the addition of CC-90010 can control the disease.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Celgene

Treatments:

Temozolomide